Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months
FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies
New study presents a human-relevant stress model for assessing potential therapeutics
Stephan brings more than 20 years of leadership experience in the pharmaceutical industry
Through this acquisition Merck has added Ohtuvayre (ensifentrine) to its growing cardio-pulmonary pipeline and portfolio
New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain
These products strengthen poultry immunity, improve productivity, and support sustainable farming practices~
Subscribe To Our Newsletter & Stay Updated
